ReviewCancer reports (Hoboken, N.J.)2025
A Case of Hepatosplenic Gamma Delta T Cell Lymphoma With Concomitant Bone Marrow Aplasia Following Azathioprine Therapy, Treatment Course and Review of the Literature.
Review in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Translational potential of γδ T cells in hematologic diseases: from immunobiology to therapeutic innovation.Frontiers in immunology · 2026Review
- A Case of Hepatosplenic Gamma Delta T Cell Lymphoma With Concomitant Bone Marrow Aplasia Following Azathioprine Therapy, Treatment Course and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive subtype of peripheral T-cell lymphoma with a poor prognosis, primarily affecting young adult males, many with a background of immunosuppression or autoimmune disease. CASE: We present the case of a 27-year-old male previously treated with azathioprine who developed pancytopenia. Bone marrow biopsy revealed severe aplasia with partial infiltration by gamma-delta T-lymphocytes (Tγδ). A definitive diagnosis of HSTCL was established through liver biopsy. The patient received induction chemotherapy with the Ifosfamide, Carboplatin, Etoposide (ICE regimen) but remained pancytopenic, prompting allogeneic stem cell transplantation. Sixty months post-treatment, he remains in complete remission.
conclusionTo our knowledge, this is the first reported case of HSTCL presenting concurrently with aplastic anemia in the context of prior azathioprine exposure. The underlying pathophysiology is likely multifactorial, involving both immune-mediated suppression and drug-induced toxicity. Clinicians should maintain a high index of suspicion for lymphoma in patients developing unexplained pancytopenia while on azathioprine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.